The Summary of Product Characteristics (SPC) for Senvelgo 15 mg/ml Oral Solution for Cats has been updated by the Medicines and Healthcare products Regulatory Agency (MHRA) following monitoring of pharmacovigilance data.
The updated SPC reflects changes in the product's indication and precautions for use. The product is now indicated for the reduction of hyperglycaemia in cats with non-insulin-dependent diabetes mellitus.
Additional information has been added to the SPC regarding the selection of patients for treatment and potential adverse events, including vomiting and diabetic ketoacidosis (DKA). The update aims to provide clearer guidance for veterinarians and pet owners.
The MHRA encourages anyone who is aware of an adverse event to report to the Marketing Authorisation Holder (pharmaceutical company) or the Veterinary Medicines Division (VMD). Reporting of adverse events is critical to ongoing monitoring activities to protect animal health, public health, and the environment.
The updated SPC is now available on the Product Information Database, and the reporting of adverse events is encouraged to ensure the ongoing safety of the product.